<DOC>
	<DOCNO>NCT02013544</DOCNO>
	<brief_summary>The purpose study confirm efficacy intravaginal prasterone ( DHEA ) symptoms vulvovaginal atrophy due menopause collect data subject expose intravaginal DHEA order meet ICH E1 guideline requirement .</brief_summary>
	<brief_title>Intravaginal Prasterone ( DHEA ) Against Vulvovaginal Atrophy Associated With Menopause</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>Main criterion : Postmenopausal woman ( hysterectomized ) Women 40 80 year age Women â‰¤5 % superficial cell vaginal smear baseline Women vaginal pH 5 baseline Women selfidentified moderate severe symptom ( ) vaginal atrophy Willing participate study sign inform consent Main criterion : Previous enrollment EndoCeutics study perform intravaginal DHEA Previous diagnosis cancer , except skin cancer ( non melanoma ) Clinically significant metabolic endocrine disease ( include diabetes mellitus ) control medication The administration investigational drug within 30 day screen visit Clinically significant abnormal serum biochemistry , urinalysis hematology</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Vulvovaginal atrophy ( VVA )</keyword>
	<keyword>Vaginal atrophy</keyword>
	<keyword>Atrophic vaginitis</keyword>
	<keyword>prasterone</keyword>
	<keyword>DHEA</keyword>
</DOC>